Product Details
| Product Name:
ML-031 |
CAS No.:
852230-33-2 |
| Purity:
99.21% |
Supply Ability:
10g |
| Release date:
2025/09/11 |
Product Introduction
Bioactivity
| Name | ML-031 |
| Description | ML-031 activated S1P2 with an EC50 value of 1 μM in an S1P reporter assay. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (138.73 mM), Sonication is recommended. Ethanol : 5 mg/mL (15.41 mM), Sonication is recommended.
|
| Keywords | S1PReceptor | S1PR2 | S1P2 | S1P Receptor | ML-031 | ML031 | ML 031 | Lysophospholipid Receptor | LPL Receptor | Inhibitor | inhibit | CYM-5482 | CYM5482 | CYM 5482 | cancer |
| Inhibitors Related | Fingolimod hydrochloride | SLP9101555 | BMS-960 | LX-2931 | CYM50374 | K145 hydrochloride | ASP-4058 | Ceranib-2 | Siponimod | Fingolimod | MP-A08 | Ozanimod |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:89159-60-4
$50.00 / 1mg
-
CAS:1422269-30-4
$30.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$30.00/1kit |
VIP1Y
|
Shenzhen Aoxi Technology Co., Ltd.
|
2025-03-15 |
|
|
$5.00/1Box |
VIP1Y
|
Hebei Jiafan Trading Company Limited
|
2024-12-24 |
|
|
$0.00/1box |
VIP1Y
|
Shanghai Yimeixin Technology Co., LTD
|
2025-09-26 |